Locally manufactured active pharmaceutical ingredients have received European Commission recognition, removing the need for a written confirmation from Singapore’s Health Sciences Authority (HSA) when they are exported to the EU. The move will make export procedures simpler and faster.
In a statement on Wednesday (18 November), HSA said the European Commission had adopted a decision on Sunday (15 November) recognising that Singapore’s Good Manufacturing Practice (GMP) standards and regulatory framework for active pharmaceutical ingredients (APIs) provide a level of public health protection equivalent to that of the EU. APIs are the core substances in medicines that produce the intended therapeutic effects.
Under the new arrangement, manufacturers exporting locally produced APIs for human medicines to the EU will no longer need to apply for written confirmation of compliance with manufacturing standards and regulatory oversight of their facilities. This will streamline administrative processes while continuing to safeguard the quality of medicines for patients.
Singapore joins a small group of countries, including the US, Japan, Switzerland and South Korea, that have received equivalent recognition from the EU. HSA has implemented an enhanced regulatory framework since December 2023 and successfully completed a comprehensive European Commission assessment, which included an on-site audit in March this year.
On 10 November, HSA also signed a working arrangement with the European Commission’s Directorate-General for Health and Food Safety and the European Medicines Agency to promote information sharing, expert exchanges and the exploration of joint regulatory reviews. The arrangement deepens cooperation in medicines and medical devices, helping patients gain faster access to safe and effective medical products.
HSA chief executive officer Adjunct Professor Raymond Chua said the recognition reflected international confidence in Singapore’s regulatory system. It reduces unnecessary administrative requirements while safeguarding patient safety, further strengthening regulatory trust and connectivity between Singapore and the EU.